ClinicalTrials.gg
RecruitingNCT06769698Updated Oct 22, 2026

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of FDC fianlimab+cemiplimab and Cemiplimab in Head and Neck Squamous Cell Carcinoma (HNSCC), sponsored by Regeneron Pharmaceuticals. Recruiting at 38 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 22, 2026First site in Poland3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cemiplimab in Squamous Cell Carcinoma of Head and Neck — 3 open to participants now, 8 under way, none of them phase 3. cemiplimab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
Largest of 10
120 · median 42
Started
2026
the only one that year
Phase 2
8 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
2 of 10
Regeneron Pharmaceuticals

Among the 10 studies testing cemiplimab in Squamous Cell Carcinoma of Head and Neck, this one has the largest planned enrollment, is the only one that started in 2026, is one of 8 in phase 2, and was the 9th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

3 of the 10 studies testing cemiplimab in Squamous Cell Carcinoma of Head and Neck are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cemiplimab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form.

The study is focused on participants with head and neck cancers who have not been previously treated for head and neck cancer that has come back or spread to other parts of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drugs
  • How much of each study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug(s) individually (which could make the study drugs less effective or could lead to side effects)
  • Compatible research to better understand the study drugs and HNSCC
03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma (HNSCC)

Keywords

  • Recurrent or Metastatic (R/M)
  • Positive for Programmed Death Ligand 1 (PD-L1) Expression
  • Human Papillomavirus (HPV)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Have confirmed (by local pathology) R/M HNSCC that is considered incurable by local therapies
  2. Primary tumor location of oral cavity, oropharynx, larynx, or hypopharynx (patients with cervical neck node SCC with occult primary as described in the protocol
  3. expression Combined Positive Score (CPS) ≥1 documented with a previously PD-L1 obtained Immunohistochemistry (IHC) result prior to screening, as described in protocol
  4. Oropharynx cancer participants only: HPV status, based on a previously documented result prior to screening, must have been established in a surgical specimen or a core biopsy specimen as described in the protocol
  5. At least 1 lesion that is measurable by (RECIST) v1.1 as described in the protocol
  6. (ECOG) performance status of 0 or 1
  7. Adequate organ and bone marrow function as described in the protocol

Key Exclusion Criteria:

Medical Conditions

  1. Participants who have Progressive Disease (PD) within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC as described in the protocol
  2. Participants who have a primary tumor site of nasopharynx, paranasal sinus or salivary gland (any histology)
  3. Head and neck SCC with unknown primary site as described in the protocol
  4. Participants with active, known, or suspected disease that has required systemic therapy within 5 years of the projected enrollment date as described in the protocol
  5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of to assist with management
  6. History or current evidence of significant cardiovascular disease including, myocarditis, congestive heart failure (as defined by Functional Classification III and IV), unstable angina, serious uncontrolled arrhythmia, and myocardial infarction 6 months prior to study enrollment.

    Prior/Concomitant Therapy

  7. Participants who have received prior systemic anticancer therapy in the R/M HNSCC setting as described in the protocol
  8. Participants with a condition requiring corticosteroid therapy (>10 mg prednisone/prednisolone/day or equivalent) within 14 days of the first dose of study drug as described in the protocol

Note: Other protocol defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Approximately 60 participants with HPV (human papillomavirus) positive HNSCC. Randomized 1:1 to Fianlimab + Cemiplmab Fixed Dose Combination (FDC) versus Cemiplimab + Placebo.

    Drug: FDC fianlimab+cemiplimab · Drug: Cemiplimab · Drug: Placebo

  • Experimental
    Cohort 2

    Approximately 60 participants with HPV negative HNSCC. Randomization is the same as in Cohort 1.

    Drug: FDC fianlimab+cemiplimab · Drug: Cemiplimab · Drug: Placebo

Interventions

  • DrugFDC fianlimab+cemiplimab

    Drug page: Fianlimab

    Fixed-Dose Combination (FDC) Administered per the protocol

    Also known as: REGN3767, REGN2810, Libtayo

  • Administered per the protocol

    Also known as: R2810, Libtayo

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Time frame: Up to 90 days after last study treatment, approximately 58 months

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  2. Severity of AEs

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  3. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  4. Incidence of immune-mediated Adverse Events (imAEs)

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  5. Incidence of treatment-related AEs

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  6. Incidence of Adverse Events of Special Interest (AESIs)

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  7. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  8. Incidence of AEs leading to discontinuation

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  9. Incidence of AEs leading to death

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  10. Incidence of laboratory abnormalities

    Per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  11. Disease Control Rate (DCR) per investigator assessment

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  12. Duration of Response (DOR) per investigator assessment or death, whichever occurs first

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  13. Progression-Free Survival (PFS) per investigator assessment or death, whichever occurs first

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  14. Concentrations of cemiplimab in serum

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  15. Concentrations of fianlimab in serum

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  16. Incidence of Anti-Drug Antibody (ADA) to fianlimab

    Time frame: Up to 90 days after last study treatment, approximately 58 months

  17. Titer of ADA to fianlimab

    Time frame: Up to 90 days after last study treatment, approximately 58 months

07

Study locations

38 of 38 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 25 months after the start.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 25 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 10, 2025
StartActual
Apr 14, 2026
Primary completionEst.
Jun 4, 2028
CompletionEst.
Dec 28, 2030
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in Poland
Show 3 added (1 Spain, 1 Italy, 1 Poland)
  • University Hospital Vall d'Hebron · Barcelona, Spain
  • Fondazione Irccs Istituto Nazionale dei Tumori di Milano · Milan, Italy
  • Wojewodzki Szpital im. Sw. Ojca Pio · Przemyśl, Poland
across 2 updates, Oct 15, 2026 – Oct 22, 2026
Show all 2 updates
  1. Oct 22, 2026
    2 sites added — first site in Poland
    Show 2 added (1 Italy, 1 Poland)
    • Fondazione Irccs Istituto Nazionale dei Tumori di Milano · Milan, Italy
    • Wojewodzki Szpital im. Sw. Ojca Pio · Przemyśl, Poland
  2. Oct 15, 2026
    1 site added
    Show site
    • University Hospital Vall d'Hebron · Barcelona, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06769698
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
Apr 14, 2026
Primary completion
Jun 4, 2028 (estimated)
Completion
Dec 28, 2030 (estimated)
Last update
Oct 22, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fianlimab · Cemiplimab

Start the discussion